Chemours Faces Securities Lawsuit Over Disclosures and Guidance
1 day ago
Chemours Co faces a securities class action lawsuit concerning Opteon demand and 2026 financial guidance disclosures. While investors view the stock as undervalued at $13.61 versus an $18.56 fair value, PFAS settlements and TiO2 pricing remain key risks.
Simply Wall Street